CBD Did Not Cause DNA Damage in Human Liver Cells, Countering Previous Safety Concerns

CBD (5–50 μM, 3–72h incubation) did not induce DNA double-strand breaks in HepG2 cells. The study also investigated CB1/CB2 receptor expression balance in HepG2 cells, providing context for understanding CBD's interactions with liver cells. Results counter previous reports of CBD-induced genotoxicity in liver cell lines.

HepG2 human liver-derived cells treated with CBD at 5–50 μM for 3–72 hours. DNA double-strand breaks assessed alongside CB1/CB2 cannabinoid receptor expression analysis and cell proliferation measurements.

Previous studies raised concerns that CBD might damage DNA in liver cells at low concentrations, potentially limiting its therapeutic applications. This study provides reassuring evidence that CBD does not cause the most dangerous form of DNA damage (double-strand breaks) in a relevant liver cell model.

Safety concerns about CBD have increased as millions of people take it daily. This study is part of an important scientific conversation about CBD's true safety profile, and finding no DNA damage in liver cells — where CBD is metabolized — is reassuring for both consumers and regulators.

Single cell line (HepG2) may not represent all liver cell types. In vitro conditions differ from in vivo metabolism. Only assessed double-strand breaks — other forms of DNA damage not tested. Does not address long-term cumulative exposure. Discrepancy with previous studies needs further investigation.